



**STI & HIV 2021 World Congress – Virtual**

***SpeeDx Symposium***

***Gonorrhoea & Resistance Guided Therapy (RGT) – What is it? Why is it needed? & How can it be implemented?***

**Friday, 16 July, 14:20-15:20hrs. CEST**

**Synopsis:**

As gonorrhoea AMR rates rise there is increasing value in utilising alternative treatment options as a strategy to preserve last line antibiotics. Helen Fifer, Public Health England, outlines the rationale of BASHH's recommendation of RGT to facilitate use of alternate treatments for gonorrhoea. Dr. Andrew Winter, Consultant in Sexual Health and HIV, discusses the steps required and challenges overcome to effectively implement RGT into both a laboratory and clinical setting.

**Speakers:**

---

Helen Fifer, Public Health England **(15 minutes)**

Consultant Microbiologist, Blood Safety, Hepatitis, STI & HIV Division, Public Health England

**Title:**

Failure of empiric therapy for gonorrhoea

**Synopsis of talk:**

- This talk will provide an overview of the emergence of resistance in *Neisseria gonorrhoeae*, illustrated by some cases of ceftriaxone-resistant gonorrhoea. The new UK guidelines and resistance-guided therapy will also be discussed.

Dr Andrew Winter, Consultant in Sexual Health and HIV, NHS Greater Glasgow and Clyde, UK **(15 minutes)**

Dr Elizabeth Moss, Clinical Fellow in Emergency Medicine, NHS Greater Glasgow and Clyde, UK

- **In this session we will share practical learning from our experience introducing molecular resistance testing for gonorrhoea in a large urban population in the UK. We will look at some of the implementation considerations such as laboratory test nomenclature, human factors issues in clinical electronic systems, and changes to service flow. We will describe some of the health technology systems that have helped, and emphasise the importance of close working between laboratory and clinical colleagues.**

**Moderator:** Dr Charles Cartwright, Senior Vice President of clinical affairs, SpeeDx